Actively Recruiting
Modulation of THC Effects by CBD: a Dose-ranging Study
Led by Centre hospitalier de l'Université de Montréal (CHUM) · Updated on 2025-12-22
100
Participants Needed
1
Research Sites
131 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purposes of this study are 1) to determine if CBD modulates THC-induced acute psychoactive effects at different CBD:THC ratios, compared with the control product (0:20, 20:20, 40:20, 80:20, 120:20) and 2) to determine if different doses of CBD modulate other THC induced behavioral effects, compared with the control product and 3)To explore qualitatively whether CBD modulates THC effects by mechanisms that are not detected with standard clinical research tools.
CONDITIONS
Official Title
Modulation of THC Effects by CBD: a Dose-ranging Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Between 21 and 49 years of age, inclusively
- Have used cannabis at least once in their lifetime
- Have used cannabis three days or less in the 30 days prior to enrollment
- Be able to provide a signed informed consent
- Willing to comply with study procedures and requirements
- Have a forced expiratory volume in first second (FEV) less than or equal to 90 %
- Able to communicate and understand English or French
- For female participants with no childbearing potential: postmenopausal for at least 12 months and 45 years or older, or surgically sterilized
- For female participants with childbearing potential: negative pregnancy test at screening and subsequent visits, no pregnancy plan during study, and use of medically accepted birth control throughout the study
You will not qualify if you...
- Any disabling medical condition that precludes safe participation or informed consent
- Severe psychiatric conditions including schizophrenia, schizoaffective disorder, bipolar disorder, current acute psychosis, mania, or suicidality
- Other disabling, unstable, or acute mental conditions preventing safe participation or consent
- Known chronic liver disease or elevated liver enzymes at screening
- Blood pressure higher than 130/80 mmHg
- Kidney disorders
- Bleeding disorders
- Current moderate or severe substance use disorder (except nicotine)
- Currently pregnant, breastfeeding, or planning pregnancy during the study
- Pending legal action or other issues preventing study completion
- Use of medication within 7 days prior to sessions that may interact with cannabis
- Participation in other cannabis or cannabinoid studies within 30 days before randomization
- Resting heart rate over 100 beats per minute
- Body mass index over 29.9 kg/m2
- Clinically significant electrocardiogram abnormalities at screening visit
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre de recherche du Centre Hospitalier Universitaire de Montréal
Montreal, Quebec, Canada, H2X0A9
Actively Recruiting
Research Team
P
Pamela Lachance, PhD
CONTACT
F
François-Olivier Hébert, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
OTHER
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here